Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) - Essential thrombocytosis - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-03-02 15:52:12 Medicine Chemistry Clinical medicine Lactams Clinical pharmacology Orphan drugs Anagrelide Adverse effect Thrombocytosis Ranitidine Essential thrombocytosis Hydroxycarbamide		Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) Add to Reading List Source URL: www.shirecanada.com Download Document from Source Website File Size: 2,84 MB Share Document on Facebook

	Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) DocID: 1m6q1 - View Document
	Registered PM (EN) 09-Mar-2015: Administrative NDS - Company name change (New 3D version to include the Submission Control No) DocID: 1lIPi - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AGRYLIN safely and effectively. See full prescribing information for AGRYLIN. AGRYLIN® (anagrelide hydrochloride) c DocID: Khvt - View Document
	Brief Report Survival of Patients With PMF Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: DocID: DtHv - View Document
	M:aDocuments20-333-executive-summary.doc DocID: B71X - View Document